Pattern Pharma's lead product, PAR-1, is the culmination of more than two decades of work by Company Principals on the activation of the innate immune system, to address the immune dysregulation which underlies infectious diseases and cancers.

PAR-1 is administered systemically to activate monocytes/macrophages, dendritic cells (DCs) and NK cells via TLR4. It is the next generation of an earlier product which has been approved and seen widespread use.

PAR-1 is efficacious as an activator of antiviral and antibacterial immune responses. In cancer applications, PAR-1 activated immune cells become tumoricidal and, since they sit at the top of the immune response stack, trigger subsequent adaptive immune responses and also enable other immune-oncology modalities such as checkpoint inhibitors. These uses are supported by extensive animal and human data as regards both efficacy and safety.

The Company utilizes a proprietary, readily-scalable process to manufacture PAR-1. It also has an issued composition of matter patent.